This finding highlights that under the same oncogenic Kras driver, different secondary mutations can lead to alterations in signaling pathways driving PDAC progression, supporting a model in which mesenchymal features of cancer cells are acquired later in the disease process [45]. Here, KRAS is linked to cancer.